ANI Pharmaceuticals (ANIP) M&A Announcement summary

Deal rationale and strategic fit

• Expands ANI's Rare Disease business, making it the largest future growth driver and accounting for about 45% of pro forma 2024 revenues.

• Adds ILUVIEN and YUTIQ, two durable commercial ophthalmology assets with significant growth potential and high barriers to genericization.

• Enhances geographic diversification with Alimera's direct operations in Europe, partnerships in Asia and the Middle East, and presence in over 20 countries.

• Leverages ANI's existing Rare Disease infrastructure and expands reach to over 3,600 ophthalmologists, with over 50% prescriber overlap.

• Aligns with ANI's M&A strategy to acquire assets with growth, durability, and patent protection in priority therapeutic areas.

Financial terms and conditions

• ANI to acquire all outstanding shares of Alimera for $5.50 per share in cash, plus a non-tradable CVR of up to $0.50 per share based on 2026 and 2027 revenue targets.

• The deal values Alimera at approximately $381 million upfront, with a total potential CVR payout of $29 million.

• ANI will repay $72.5 million of Alimera debt, net of estimated cash at close.

• The $5.50 per share price represents a 75% premium to Alimera's closing price on June 21, 2024.

• Funded by cash on hand and $280 million in committed financing from J.P. Morgan and Blackstone.

Synergies and expected cost savings

• Expected to deliver $35–$38 million in 2025 adjusted non-GAAP EBITDA, including about $10 million in identified cost synergies.

• Additional EBITDA contribution anticipated from accelerated growth of Cortrophin Gel in ophthalmology.

• Combined sales force of approximately 45 reps to drive commercial efficiencies and expand reach to ~3,600 ophthalmologists.

• Significant overlap among high-potential prescribers to maximize product utilization.

• Anticipates high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025, with substantial accretion thereafter.